The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1531
ISSUE 1531
October 9, 2017
Influenza Vaccine for 2017-2018
| The full article is available to subscribers | Subscriber Login |
October 9, 2017 (Issue: 1531)
Revised 1/26/18: In Table 2, the recommended age for Fluarix Quadrivalent was changed to ≥6 months.
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.1
EFFECTIVENESS — The effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza illness depends on the match between the vaccine and circulating strains. Vaccine effectiveness is highest (40-60%) when the match is close, but even when the match is poor, vaccination has been shown to reduce the risk of hospitalization and death from influenza.2-4 For the 2016-2017 influenza season, the adjusted overall effectiveness of the seasonal influenza vaccine against influenza A and B viruses was 42%.5
COMPOSITION — All seasonal influenza vaccines available in the US contain the same two influenza A virus
... more- LA Grohskopf et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices – United States, 2017-2018 influenza season. MMWR Recomm Rep 2017; 66:1.
- EA Belongia et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016; 16:942.
- M Darvishian et al. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. Lancet Infect Dis 2014; 14:1228.
- B Flannery et al. Influenza vaccine effectiveness against pediatric deaths: 2010-2014. Pediatrics 2017; 139:e20164244.
- CDC. Influenza vaccine effectiveness 2016-2017. Advisory Committee on Immunization Practices meeting. Available at: www. cdc.gov. Accessed September 28, 2017.
- R Ray et al. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Hum Vaccin Immunother 2017; 13:1640.
- WEP Beyer et al. Rationale for two influenza B lineages in seasonal vaccines: a meta-regression study on immunogenicity and controlled field trials. Vaccine 2017; 35:4167.
- JR Chung et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics 2016; 137:e20153279.
- ML Jackson et al. Influenza vaccine effectiveness in the United States during the 2015-2016 season. N Engl J Med 2017; 377:534.
- B Young et al. Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Vaccine 2017; 35:212.
- JY Song et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010; 28:3929.
- JC King Jr et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 2009; 27:6589.
- R Baxter et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011; 29:2272.
- LM Dunkle et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med 2017; 376:2427.
- CA DiazGranados et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014; 371:635.
- S Gravenstein et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med 2017; 5:738.
- DK Shay et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012-2013 and 2013-2014. J Infect Dis 2017; 215:510.
- Fluad – an adjuvanted seasonal influenza vaccine for older adults. Med Lett Drugs Ther 2016; 58:8.
- SE Frey et al. Comparison of the safety and immunogenicity of an MF59-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014; 32:5027.
- PG Van Buynder et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013; 31:6122.
- S Mannino et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012; 176:527.
- JA Udell et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013; 310:1711.
- C Clar et al. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev 2015; 5:CD005050.
- MG Thompson et al. Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons. Clin Infect Dis 2014; 58:449.
- SA Madhi et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014; 371:918.
- JG Donahue et al. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12. Vaccine 2017; 35:5314.
- CDC. Flu vaccination & possible safety signal: information & guidance for health care providers. Available at: www.cdc.gov. Accessed September 28, 2017.
- American Congress of Obstetricians and Gynecologists. It is safe to receive flu shot during pregnancy. Available at: www. acog.org. Accessed September 28, 2017.
- JC Kwong et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis 2013; 13:769.
- LL Polakowski et al. Chart-confirmed Guillain-Barré syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010. Am J Epidemiol 2013; 178:962.
- A Des Roches et al. Egg-allergic patients can be safely vaccinated against influenza. J Allergy Clin Immunol 2012; 130:1213.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Influenza Vaccine for 2017-2018
Article code: 1531a
Electronic, downloadable article - $45
Article code: 1531a
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
